Amgen's strategy includes integrated activities intended to maintain and strengthen its competitive position in the industry, focusing on six commercial areas and conducting discovery research primarily in three therapeutic areas. The company has advanced its innovative pipeline and maintained a strategic and disciplined approach to capital allocation while advancing its environmental, social, and governance (ESG) efforts. In 2021, Amgen continued to advance its pipeline, achieving key regulatory approvals and engaging in external business development activities, which included acquiring technologies and entering into licensing agreements to enhance its research capabilities. The company devotes considerable resources to research and development (R&D) activities, which are critical for successful product development in the biotechnology industry, an area characterized by high uncertainty. Amgen's approach to human capital resource management is directed at attracting, motivating, developing, and retaining talent, which is essential for tackling the challenges of running an enterprise focused on the discovery, development, and commercialization of innovative medicines. The company believes that a diverse and inclusive culture fosters innovation, supporting its ability to serve patients. Amgen's financial activities reflect a commitment to optimizing its capital structure, deploying accumulated cash balances strategically, and considering various alternatives, including strategic transactions, debt repayment, dividends, and stock repurchases. The company emphasizes the importance of mobilizing and deploying IT-based resources in combination with leveraging the value of other resources and capabilities to support business needs and enhance operational efficiency. Amgen's investment in technology and infrastructure is aimed at improving its capabilities in data management, information reliability, and operational flexibility, which are essential for responding to market dynamics and consumer demands. The company has also faced challenges due to increased competition from biosimilars and generics, which have pressured product sales and necessitated a focus on innovation and strategic resource allocation. The ongoing COVID-19 pandemic has impacted Amgen's operations, prompting the company to adapt its business processes and maintain critical operations while monitoring changes in demand patterns for its products. Amgen's commitment to environmental sustainability and its long-term targets reflect its strategic alignment with broader societal goals, further enhancing its organizational capabilities. The company recognizes the need for continuous evaluation of its performance metrics and strategic management practices to ensure effective decision-making and resource deployment in a rapidly changing business environment.